Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Biohaven Ltd.BHVN · Entity 4379 | Director | April 28, 2026 | May 01, 2026 |
| Biohaven Pharmaceutical Holding Co Ltd.BHVN · Entity 123269 | Director | October 03, 2022 | October 03, 2022 |
| Serina Therapeutics, Inc.SER · Entity 9581 | Director | June 17, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Biohaven Ltd.
Report date April 28, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.61 · Expires 2036-04-28 | Direct | 68,693 |
Reported balance
After 2026-04-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-28 · Grant · Acquired 68,693 · Balance 68,693 F1: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.
Biohaven Pharmaceutical Holding Co Ltd.
Report date October 03, 2022 · Filed October 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 1
1 source rowRow 1 · 2022-10-03 · Disposition to issuer · Disposed 2,583,658 · Balance 0 F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration"). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $95.33 · Expires 2032-04-28 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-03 · Disposition to issuer · Disposed 8,239 · Balance 0 F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.17 · Expires 2031-05-05 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-03 · Disposition to issuer · Disposed 11,996 · Balance 0 F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.94 · Expires 2030-04-29 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-10-03 · Disposition to issuer · Disposed 18,000 · Balance 0 F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.24 · Expires 2029-05-20 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-10-03 · Disposition to issuer · Disposed 18,000 · Balance 0 F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").
F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration").
F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
Serina Therapeutics, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,897,445 |
Reported balance
After 2026-06-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-17 · Conversion · Acquired 1,770,805 · Balance 1,897,445 F1: Shares reflect the mandatory conversion at an adjusted Conversion Price of $2.25 of the Company's Series A Convertible Preferred Stock ("Series A Preferred") issued in connection with the April 2025 Private Placement. The Reporting Person was originally issued 762,548 shares of Series A Preferred that were converted into 1,755,555 shares of Common Stock and 15,250 shares that were issued for payment of accrued dividends. Shares were issued upon receipt of stockholder approval, which approval was obtained on June 17, 2026, and the underlying Common Stock shares were issued on June 17, 2026. F2: The share ownership amount has been updated to reflect the correct number of shares beneficially owned by the Reporting Person. |
| Common StockSEC Table I · non-derivative | Direct | 8,564,382 |
Reported balance
After 2026-06-17 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-06-17 · Conversion · Acquired 6,666,667 · Balance 8,564,382 F3: Issued pursuant to a Securities Purchase Agreement dated March 17, 2026, at a purchase price of $2.2499 per pre-funded warrant (reflecting a $0.0001 exercise price). The Pre-Funded Warrants have no expiration date and are subject to customary beneficial ownership limitations. The exercise price and share count are subject to adjustment for stock splits, dividends, and similar events. Under NYSE American rules, issuance of the underlying shares to the reporting person is subject to prior stockholder approval which was obtained on June 17, 2026, thereby triggering the automatic conversion of the Pre-Funded Warrants into common stock. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.98 · Expires 2036-06-17 | Direct | 15,250 |
Reported balance
After 2026-06-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-17 · Grant · Acquired 15,250 · Balance 15,250 F4: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
| Redeemable WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2030-03-17 | Direct | 3,333,333 |
Reported balance
After 2026-06-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-17 · Grant · Acquired 3,333,333 · Balance 3,333,333 F5: Issued pursuant to the same Securities Purchase Agreement dated March 17, 2026, covering 50% of the shares underlying the Pre-Funded Warrants acquired by the reporting person. The Company may call the warrants at $0.01 per underlying share upon 30 days' notice if the Common Stock closing price equals or exceeds $10.00 on the business day prior to the redemption notice, on the earlier of (i) 30 days after first patient dosing in Cohort 2 of the Company's SER-252 Phase 1b SAD study or (ii) September 30, 2026. Holders have 30 days to exercise following a call notice. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $5.18 | Direct | 0 |
Reported balance
After 2026-06-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-17 · Conversion · Disposed 762,548 · Balance 0 F6: The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares reflect the mandatory conversion at an adjusted Conversion Price of $2.25 of the Company's Series A Convertible Preferred Stock ("Series A Preferred") issued in connection with the April 2025 Private Placement. The Reporting Person was originally issued 762,548 shares of Series A Preferred that were converted into 1,755,555 shares of Common Stock and 15,250 shares that were issued for payment of accrued dividends. Shares were issued upon receipt of stockholder approval, which approval was obtained on June 17, 2026, and the underlying Common Stock shares were issued on June 17, 2026.
F2: The share ownership amount has been updated to reflect the correct number of shares beneficially owned by the Reporting Person.
F3: Issued pursuant to a Securities Purchase Agreement dated March 17, 2026, at a purchase price of $2.2499 per pre-funded warrant (reflecting a $0.0001 exercise price). The Pre-Funded Warrants have no expiration date and are subject to customary beneficial ownership limitations. The exercise price and share count are subject to adjustment for stock splits, dividends, and similar events. Under NYSE American rules, issuance of the underlying shares to the reporting person is subject to prior stockholder approval which was obtained on June 17, 2026, thereby triggering the automatic conversion of the Pre-Funded Warrants into common stock.
F4: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
F5: Issued pursuant to the same Securities Purchase Agreement dated March 17, 2026, covering 50% of the shares underlying the Pre-Funded Warrants acquired by the reporting person. The Company may call the warrants at $0.01 per underlying share upon 30 days' notice if the Common Stock closing price equals or exceeds $10.00 on the business day prior to the redemption notice, on the earlier of (i) 30 days after first patient dosing in Cohort 2 of the Company's SER-252 Phase 1b SAD study or (ii) September 30, 2026. Holders have 30 days to exercise following a call notice.
F6: The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 25, 2019 Filed Apr 5, 2019 17:54 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 107,500 | $9.29 | $998,675.00 |
DisclosureSEC source: 0001209191-19-023860 · doc4.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,582,601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 20:09 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | GrantOption to Purchase Common Stock · Derivative | 100,000 | $0.00 Strike: $4.28 | $0.00 |
DisclosureSEC source: 0000908662-19-000094 · edgar.xml · derivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-03-10 F1 · derivative.exercise_date: Options will become exercisable in four equal quarterly installments from the date of grant on March 11, 2019 provided that the grantee remains a director on the last day of the applicable calendar quarter. Read SEC document |
| May 01, 2018 Filed May 3, 2018 17:23 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $28.76 | $0.00 |
DisclosureSEC source: 0001209191-18-027727 · doc4.xml · derivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Shares · 18,000 shares Expires 2028-04-30 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 1, 2019 or (b) the date of the 2019 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 18:17 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 23,320 | $34.32 | $800,342.40 |
DisclosureSEC source: 0001209191-18-007146 · doc4.xml · nonDerivative · entry 3 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,475,101 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on August 19, 2017. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.08 - $34.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 18:17 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 18,280 | $33.42 | $610,917.60 |
DisclosureSEC source: 0001209191-18-007146 · doc4.xml · nonDerivative · entry 2 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,498,421 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on August 19, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.07 - $34.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 18:17 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 8,400 | $32.63 | $274,092.00 |
DisclosureSEC source: 0001209191-18-007146 · doc4.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,516,701 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on August 19, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.07 - $33.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 19:28 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 16,000 | $32.79 | $524,640.00 |
DisclosureSEC source: 0001209191-18-005479 · doc4.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,525,101 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on August 19, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.50 - $33.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| January 22, 2018 Filed Jan 23, 2018 18:57 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 9,000 | $32.51 | $292,590.00 |
DisclosureSEC source: 0001209191-18-004994 · doc4.xml · nonDerivative · entry 4 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,541,101 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on August 19, 2017. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.50 - $32.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) to this Form 4. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 18:57 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 15,939 | $31.08 | $495,384.12 |
DisclosureSEC source: 0001209191-18-004994 · doc4.xml · nonDerivative · entry 3 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,550,101 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on August 19, 2017. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.75 - $31.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 18:57 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 17,249 | $30.18 | $520,574.82 |
DisclosureSEC source: 0001209191-18-004994 · doc4.xml · nonDerivative · entry 2 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,566,040 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on August 19, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.75 - $30.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 18:57 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 6,812 | $29.20 | $198,910.40 |
DisclosureSEC source: 0001209191-18-004994 · doc4.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,583,289 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on August 19, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.75 - $29.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 18:37 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 40,000 | $26.52 | $1,060,800.00 |
DisclosureSEC source: 0001209191-18-004374 · doc4.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,590,101 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on August 19, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.25 - $27.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. F3 · balance_after: Includes 1,459,802 shares received by the Reporting Person from by Portage Biotech Inc. as a distribution in kind on a pro rata basis to its shareholders, effective January 15, 2017, which transaction was not required to be reported under SEC rules. Read SEC document |
| January 04, 2018 Filed Jan 5, 2018 20:05 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 16,976 | $28.77 | $488,399.52 |
DisclosureSEC source: 0001209191-18-002587 · doc4.xml · nonDerivative · entry 2 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,170,299 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on August 19, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.65 - $29.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 20:05 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 33,024 | $28.68 | $947,128.32 |
DisclosureSEC source: 0001209191-18-002587 · doc4.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,187,275 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on August 19, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.65 - $28.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 17:58 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 13,778 | $26.73 | $368,285.94 |
DisclosureSEC source: 0001209191-17-067128 · doc4.xml · nonDerivative · entry 2 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,220,299 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on August 19, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.45 - $27.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 17:58 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 25,652 | $26.08 | $669,004.16 |
DisclosureSEC source: 0001209191-17-067128 · doc4.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,234,077 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on August 19, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.45 - $26.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| November 30, 2017 Filed Dec 1, 2017 19:27 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 3,030 | $25.47 | $77,174.10 |
DisclosureSEC source: 0001209191-17-063328 · doc4.xml · nonDerivative · entry 2 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,259,729 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on August 19, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.45 - $25.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. Read SEC document |
| November 29, 2017 Filed Dec 1, 2017 19:27 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 6,940 | $25.48 | $176,831.20 |
DisclosureSEC source: 0001209191-17-063328 · doc4.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,262,759 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on August 19, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.45 - $25.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| November 27, 2017 Filed Nov 28, 2017 19:19 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 20,000 | $25.92 | $518,400.00 |
DisclosureSEC source: 0001209191-17-062756 · doc4.xml · nonDerivative · entry 2 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,269,699 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on August 19, 2017. Read SEC document |
| November 24, 2017 Filed Nov 28, 2017 19:19 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 600 | $26.02 | $15,612.00 |
DisclosureSEC source: 0001209191-17-062756 · doc4.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,289,699 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on August 19, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 - $26.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| May 09, 2017 Filed May 9, 2017 16:44 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | ConversionSeries A Preferred Shares · Derivative | 1,076,299 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-030973 · doc4.xml · derivative · entry 3 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 1,076,299 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Effective immediately prior to the closing of the Issuer's initial public offering of its common shares, each Series A Preferred Share automatically converted into one common share of the Issuer. The Series A Preferred Shares had no expiration date. F2 · derivative.exercise_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common shares, each Series A Preferred Share automatically converted into one common share of the Issuer. The Series A Preferred Shares had no expiration date. F2 · derivative.expiration_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common shares, each Series A Preferred Share automatically converted into one common share of the Issuer. The Series A Preferred Shares had no expiration date. Read SEC document |
| May 09, 2017 Filed May 9, 2017 16:44 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | PurchaseCommon Shares | 175,000 | $17.00 | $2,975,000.00 |
DisclosureSEC source: 0001209191-17-030973 · doc4.xml · nonDerivative · entry 2 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,290,299 Read SEC document |
| May 09, 2017 Filed May 9, 2017 16:44 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | ConversionCommon Shares | 1,076,299 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-030973 · doc4.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,115,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares received upon conversion of Series A Preferred Shares. F1 · price: Represents shares received upon conversion of Series A Preferred Shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.